Clinical Trial Applicaiton (CTA) in china
In China, a Clinical Trial Application (CTA) should be submitted to the National Medical Products Administration (NMPA), to request the authorization to administer an Investigational Drug to humans. CTA can be submitted to NMPA for Phase I through Phase IV clinical trials, including bioequivalence trials, that are conducted in China.
About Global Regulatory Partners Inc:
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices and pharmaceutical companies globally. GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea GRP helps many life science companies register their products in different countries in compliance with local regulations.